A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Seasonal Allergies
NCT ID: NCT01368445
Last Updated: 2011-10-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
617 participants
INTERVENTIONAL
2006-08-31
2008-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MP03-36 Nasal Spray
azelastine hydrochloride 0.15%
azelastine hydrochloride 0.15% Nasal Spray
1644 mcg, 2 sprays per nostril twice daily AM \& PM)
MP03-36 and Placebo Nasal Spray
azelastine hydrochloride 0.15% and Placebo
azelastine hydrochloride 0.15% and Placebo
822 mcg azelastine hydrochloride 0.15%, 2 sprays per nostril once daily (AM) and 0mg placebo spray 2 sprays per nostril once daily (PM)
Azelastine 0.1%, Nasal Spray
Azelastine 0.1%, Nasal Spray
Azelastine 0.1%, Nasal Spray
1096 mcg, Azelastine 0.1%,2 sprays per nostril twice daily (AM \& PM)
Placebo Nasal Sapray
0mg, 2 sprays per nostril twice daily AM \& PM)
azelastine hydrochloride 0.15% Nasal Spray
1644 mcg, 2 sprays per nostril twice daily AM \& PM)
azelastine hydrochloride 0.15% and Placebo
822 mcg azelastine hydrochloride 0.15%, 2 sprays per nostril once daily (AM) and 0mg placebo spray 2 sprays per nostril once daily (PM)
Azelastine 0.1%, Nasal Spray
1096 mcg, Azelastine 0.1%,2 sprays per nostril twice daily (AM \& PM)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
azelastine hydrochloride 0.15% Nasal Spray
1644 mcg, 2 sprays per nostril twice daily AM \& PM)
azelastine hydrochloride 0.15% and Placebo
822 mcg azelastine hydrochloride 0.15%, 2 sprays per nostril once daily (AM) and 0mg placebo spray 2 sprays per nostril once daily (PM)
Azelastine 0.1%, Nasal Spray
1096 mcg, Azelastine 0.1%,2 sprays per nostril twice daily (AM \& PM)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Provide written informed consent/pediatric assent. If the patient is a minor, a parent or legal guardian must give written informed consent
* Screening Visit: Have a 12-hour reflective total nasal symptoms score ( TNSS) of at least 8 out of a possible 12 and a congestion score of 2 or 3 on Day -7
* Randomization Visit: Have a 12-hour reflective total nasal symptoms score (TNSS) (AM or PM) of at least 8 on 3 separate assessments (one of which was within 2 days of Day 1, and can include the morning of Day 1) during the Lead-in Period. In addition, an AM or PM nasal congestion score of 2 or 3 must have been recorded on 3 separate assessments (one of which was within 2 days of Day 1, and can include the morning of Day 1).
* Must have taken at least 10 doses of study medication during the lead-in period
* Randomization Visit: An instantaneous (TNSS) of ≥ 8 before beginning the onset of action assessment on Day 1
* Willing and able to comply with the study requirements
* At least a 2-year history of seasonal allergic rhinitis (SAR) during the fall pollen allergy season
* The presence of IgE-mediated hypersensitivity to local fall pollen confirmed by a positive response to either skin prick or intradermal testing within the last year. A positive response is defined as a wheal diameter of at least 3 mm larger than the control for the skin prick test or at least 7 mm larger than the control for the intradermal test.
* General good health and free of any disease or concomitant treatment that could interfere with the interpretation of the study results as determined by the investigator or the sponsor's medical officer
* Patients receiving immunotherapy injections (antigen desensitization) must be on a stable maintenance regimen for at least 30 days before the first study visit (adjustments to regimen following a brief period of missed injections does not preclude participation). Patients who are on maintenance doses of sublingual immunotherapy may be considered for the trial on a case-by-case basis after discussion with the sponsor's medical monitor or designee.
Exclusion Criteria
* Presence of any hypersensitivity to drugs similar to azelastine and to either sorbitol or sucralose (Splenda® brand sweetener)
* Women who are pregnant or nursing
* Women of childbearing potential who are not abstinent and not practicing a medically acceptable method of contraception
* Respiratory tract infections within two weeks prior to Day -7
* Respiratory Infections requiring oral antibiotic treatment two weeks prior to Day -7
* Other nasal disease(s) likely to affect deposition of intranasal medication, such as sinusitis, rhinitis medicamentosa or clinically significant polyposis or nasal structural abnormalities
* Patients with asthma (with the exception of mild, intermittent asthma)
* Patients with significant pulmonary disease
* Patients with a known history of alcohol or drug abuse
* Existence of any surgical or medical condition, which in the opinion of the investigator or sponsor, might significantly alter the absorption, distribution, metabolism, or excretion of study drug
* Clinically relevant abnormal physical findings within 1 week of randomization which, in the opinion of the investigator, would interfere with the objectives of the study or that may preclude compliance with the study procedures
* Planned travel outside the study area during the study period
* Family members and employees should be excluded
* Patients who received prohibited medications within specified timepoints in the protocol.
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Meda Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AABI Associates Medical Group
Fountain Valley, California, United States
West Coast Clinical Trials
Long Beach, California, United States
Allergy Research Foundation
Los Angeles, California, United States
Southern California Research
Mission Viejo, California, United States
Allergy Medical Group
Roseville, California, United States
Allergy Associates Medical Group
San Diego, California, United States
Allergy and Asthma Associates of CA
San Jose, California, United States
The William Storms Allergy Clinic
Colorado Springs, Colorado, United States
Colorado Allergy and Asthma Centers, PC
Denver, Colorado, United States
Coastal Allergy and Asthma P.C.
Savannah, Georgia, United States
Kansas City Allergy and Asthma
Overland Park, Kansas, United States
Institute for Asthma and Allergy, P.C.
Wheaton, Maryland, United States
Northeast Medical Research Associates, Inc.
North Dartmouth, Massachusetts, United States
Clinical Research Institute
Minneapolis, Minnesota, United States
The Asthma and Allergy Center, PC
Papillion, Nebraska, United States
Atlantic Allergy, Asthma & Immunology
Ocean City, New Jersey, United States
Princeton Center for Clinical Research
Skillman, New Jersey, United States
Allergy and Asthma Institue of Rochester
Rochester, New York, United States
North Carolina Clinical Research
Raleigh, North Carolina, United States
Clinical Research Center
Cincinnati, Ohio, United States
Oklahoma Institute of Allergy and Asthma
Edmond, Oklahoma, United States
Allergy and Asthma Consultants of NJ-PA, P.C
Collegeville, Pennsylvania, United States
Valley Clinical Research Center
Easton, Pennsylvania, United States
Allergy and Clinical Immunology Associates
Pittsburgh, Pennsylvania, United States
Allergy Asthma Associates Research Dept.
Austin, Texas, United States
AARA Research Center
Dallas, Texas, United States
Research Across America
Dallas, Texas, United States
Central Texas Health Research
New Braunfels, Texas, United States
Sylvana Research Associates
San Antonio, Texas, United States
Allergy and Asthma Center
Waco, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MP433
Identifier Type: -
Identifier Source: org_study_id